CompletedNot Applicable

Prevalence of Hyperprolactinemia in Systemic Scleroderma

France71 participantsStarted 2021-03-01

Plain-language summary

Systemic sclerosis is an autoimmune and inflammatory disease characterized primarily by fibrosis and vascular involvement. We know that the immune system is disrupted in systemic sclerosis, but there are probably other mechanisms to explain the disease, including deregulation of certain proteins such as prolactin

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: Scleroderma patients: * man or woman over 18 years old * with systemic sclerosis meeting ACR-EULAR 2013 criteria * having given his no opposition * being social insured Healthy subjects: * man or woman over 18 years old * donation of blood to the EFS * matched on age (+/- 5 years) and sex * having given his no opposition Exclusion Criteria: * Man or woman under 18 years old * Pregnant or breastfeeding women * Receiving medical treatment inducing dysfunction of the hypothalamic pituitary axis * Refusing or unable to give no objection

What they're measuring

the prevalence of hyperprolactinemia in scleroderma patients

Timeframe: At 2 years

Trial details

NCT IDNCT04746313

SponsorUniversity Hospital, Lille

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2021-05-12

View on ClinicalTrials.gov More Sclerosis, Systemic trials